Buradasınız

Anasayfa » Content

Kronik Böbrek Hastalığı olan Hastalarda Spironolaktonun Diastolik Kalp Fonksiyonlarına Etkisi

Effect of Spironolactone on Diastolic Heart Function in Patients with Chronic Kidney Disease

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2010
DOI: 
DOI 10.5262/tndt.2010.1003.06

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
PURPOSE: The aim of this study was to evaluate the effect of spironolactone on diastolic heart functions in patients with chronic kidney disease by tissue Doppler echocardiography. MA TERIAL and M ETHODS: Twenty-four patients (11 males, 13 females) were included to the study. The etiology of chronic kidney disease was diabetes mellitus in 14 patients (58%). Biochemical and 24-hour proteinuria analysis, blood pressure measurements, and tissue Doppler echocardiography examination were obtained before the therapy. Spironolactone (25 mg/d) was then added to the treatment. The serum potassium level was measured at the first and fourth weeks. After a period for eight weeks, all the analyses were repeated. The statistical analysis was performed using SPSS version 13.0. RESUL TS: There were significant differences between pretreatment and posttreatment lateral deceleration time, right ventricular deceleration time, and anterior late diastolic velocity (P=0.010, P<0.001, and P=0.046, respectively) by tissue Doppler echocardiography. Systolic and diastolic blood pressure was significantly reduced (P=0.006 and P=0.003, respectively). The serum potassium level was significantly increased (P=0.001). Urinary protein excretion was significantly decreased (P=0.001). CONCLU SION: This study suggests that spironolactone may improve diastolic heart functions in patients with chronic kidney disease. Hyperkalemia is the most important side effect of treatment. Further studies are needed to determine the efficacy of spironolactone on diastolic heart function.
Bookmark/Search this post with
Abstract (Original Language): 
AMA Ç: Bu çalışmanın amacı, kronik böbrek hastalığı olan hastalarda spironolaktonun diastolik kalp fonksiyonları üzerindeki etkisini doku Doppler ekokardiyografi ile incelemektir. GEREÇ ve YÖN TEML ER: Bu çalışmaya 24 hasta (11 E, 13 K) alındı. Kronik böbrek hastalığı etiyolojisi 14 hastada (%58) diabetes mellitus idi. Tedavi öncesi biyokimya ve 24 saatlik idrarda proteinüri analizleri, kan basıncı ölçümü ve doku Doppler ekokardiyografi incelemesi yapıldı. Daha sonra tedaviye 25 mg/gün spironolakton ilave edildi. Serum potasyum düzeyi 1. ve 4. haftada kontrol edildi. Sekiz haftalık tedavi sonrasında tüm analizler tekrarlandı. İstatistiksel analizler SPSS ver. 13 ile gerçekleştirildi. BUL GULA R: Doku Doppler ekokardiyografi ile tedavi öncesi ve tedavi sonrası lateral deselerasyon zamanı, sağ ventrikül deselerasyon zamanı ve anterior Am değerleri arasında istatistiksel olarak anlamlı farklılıklar bulundu (sırasıyla, P=0,010, P<0,001, ve P=0,046). Sistolik ve diastolik kan basınçları anlamlı olarak azaldı (sırasıyla, P=0,006 ve P=0,003). Serum potasyum düzeyi anlamlı düzeyde arttı (P=0,001). 24 saatlik idrarda protein atılımı anlamlı olarak azaldı (P=0,001). SONU Ç: Bu çalışma, spironolaktonun kronik böbrek hastalığı olan hastalarda diastolik kalp fonksiyonlarını düzeltebileceğini göstermektedir. Hiperpotasemi tedavinin en önemli yan etkisidir. Spironolaktonun diastolik kalp fonksiyonları üzerindeki etkisini değerlendirmek için daha fazla çalışmaya ihtiyaç vardır.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_19_pp_186-191.pdf
  • 3
186-191
  • Turkish

REFERENCES

References: 

1. Stenvinkel P, Aman K, Ketteler M: Cardiovascular disease in
chronic kidney disease. In Feehally J, Floege J, Johnson RJ (eds).
Comprehensive Clinical Nephrology. (3 th ed). Philadelphia:
Mosby Elsevier, 2007; 839-852
2. Zile MR, Bruteaer DL: New concepts in diastolic dysfunction and
diastolic heart failure. Circulation 2002; 105: 1387-1393
3. Otsuka T, Suzuki M, Yoshikawa H, Sugi K: Left ventricular diastolic
dysfunction in the early stage of chronic kidney disease. J Cardiol
2009; 54: 199-204
4. Brown NJ: Aldosterone and end-organ damage. Current Opinion in
Nephrology and Hypertension 2005; 14: 235-241
5. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone
blockade in patients with diabetic nephropathy. Hypertension 2003;
41: 64-68
6. Sato A, Saruta T, Funder JW: Combination therapy with aldosterone
blockade and renin-angiotensin inhibitors confers organ protection.
Hypertens Res 2006; 29: 211-216
7. Gulel O, Soylu K, Yuksel S, Karaoglanoglu M, Cengiz K, Dilek M,
Hamiseyev C, Kale A, Arik N: Evidence of left ventricular systolic
and diastolic dysfunction by colour tissue imaging despite normal
ejection fraction in patients on chronic hemodialysis program.
Echocardiography 2008; 25: 569-574
8. Weiner DE, Sarnak MJ: Cardiac function and cardiovascular disease
in chronic kidney disease. In Greenberg A (ed). The NKF Primer on
Kidney Disease (5 th ed). Philadelphia: Elsevier, 2009, 499-505
9. Koprowski A, Gruchala M, Rynkiewicz A: Management of left
ventricular diastolic heart failure: is it only blood pressure control?
Curr Opin Cardiol 2009; 24: 161-166
10. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR,
Love TE, Aban IB, Shlipak MG: Chronic kidney disease associated
mortality in diastolic versus systolic heart failure: A propensity
matched study. Am J Cardiol 2007; 99: 393-398
11. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T,
Ichihara S, Kato T, Ohshima S, Murase Y, Lino S, Obata K, Noda
A, Okumura K, Yokota M: Mineralocorticoid receptor antagonism
ameliorates left ventricular diastolic dysfunction and myocardial
fibrosis in mildly symptomatic patients with idiopathic dilated
cardiomyopathy: A pilot study. Circulation 2005 ; 112: 2940-2945
12. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR,
Murphy NF, Patle AK, Baugh JA, McDonald KM: Natural history
of markers of collagen turnover in patients with early diastolic
dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54:
1674-1682
13. Edvardsen T, Urheim S, Skulstad H, Steine K, Ihlen H, Smiseth
OA: Quantification of left ventricular systolic function by tissue
Doppler echocardiography: Added value of measuring pre- and
postejection velocities in ischemic myocardium. Circulation 2002;
105: 2071-2077
14. Rodriguez L, Garcia M, Ares M, Griffin BP, Nakatani S, Thomas
JD: Assessment of mitral annular dynamics during diastole by
Doppler tissue imaging: comparison with mitral Doppler inflow in
subjects without heart disease and in patients with left ventricular
hypertrophy. Am Heart J 1996; 131: 982-987
15. Hayashi SY, Rohani M, Lindholm B, Brodin LA, Lind B, Barany
P, Alvestrand A, Seeberger A: Left ventricular function in patients
with chronic kidney disease evaluated by colour tissue Doppler
velocity imaging. Nephrol Dial Transplant 2006 ; 21: 125-132
Cilt/Vol: 19, No: 3, 2010, Sayfa/Page: 186-191 191
Türk N efroloji D iyaliz ve Transplantasyon D ergisi Şengül E ve ark: Spironolaktonun Diastolik Kalp Fonksiyonlarına Etkisi
Turkish Nephrology, Dialysis and Transplantation Journal
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A,
Palensky J, Wittes J: The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. Randomized
Aldactone Evaluation Study Investigators. N Engl J Med 1999;
341: 709-717
17. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Lifethreatening
hyperkalemia during combined therapy with angiotensin-converting
enzyme inhibitors and spironolactone: An analysis of 25 cases. Am
J Med 2001; 110: 438-441
18. Navaneethen SD, Nigwekar SU, Sehgal AR, Strippoli GF:
Aldosteron antagonists for preventing the progression of chronic
kidney disease: A systematic review and meta-analysis. Clin J Am
Soc Nephrol 2009; 4: 542-551

Thank you for copying data from http://www.arastirmax.com